BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35671252)

  • 1. Thrombotic Microangiopathy Secondary to Systemic Sclerosis with Severe Complement Activation Not Responsive to Eculizumab: A Case Report.
    Nakamura M; Abe T; Ochiai H
    Am J Case Rep; 2022 Jun; 23():e936116. PubMed ID: 35671252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: A case report.
    Abe T; Sasaki A; Ueda T; Miyakawa Y; Ochiai H
    Medicine (Baltimore); 2017 Feb; 96(6):e6056. PubMed ID: 28178155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.
    Kello N; Khoury LE; Marder G; Furie R; Zapantis E; Horowitz DL
    Semin Arthritis Rheum; 2019 Aug; 49(1):74-83. PubMed ID: 30598332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eculizumab in secondary atypical haemolytic uraemic syndrome.
    Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M
    Nephrol Dial Transplant; 2017 Mar; 32(3):466-474. PubMed ID: 28339660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
    Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children.
    Schoettler ML; Patel S; Bryson E; Deeb L; Watkins B; Qayed M; Chandrakasan S; Fitch T; Silvis K; Jones J; Chonat S; Williams KM
    Transplant Cell Ther; 2024 Mar; 30(3):336.e1-336.e8. PubMed ID: 38145741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement activation and blockade in massive post-partum haemorrhage, thrombotic microangiopathy and acute kidney injury: a case report.
    Guzzo G; Kissling S; Pantaleo G; Pascual M; Sadallah S; Teta D
    BMC Nephrol; 2021 Jul; 22(1):252. PubMed ID: 34229609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding.
    Fujita Y; Terashita M; Yazawa M; Yamasaki Y; Imamura T; Kibayashi J; Sawai T; Hidaka Y; Ohtani K; Inoue N; Shibagaki Y
    Intern Med; 2020; 59(1):93-99. PubMed ID: 31902910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy associated TMA in 13-year-old patient successfully treated with Eculizumab: case report.
    Cody E; Claes D; Taylor V; Erkan E
    BMC Nephrol; 2022 Apr; 23(1):147. PubMed ID: 35428247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated thrombotic microangiopathy of the small intestine in a patient with atypical hemolytic uremic syndrome - a case report.
    Nunius C; Büttner-Herold M; Bertz S; Schiffer M; Buchholz B
    BMC Nephrol; 2020 Mar; 21(1):104. PubMed ID: 32204691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report.
    Bjørkto MH; Barratt-Due A; Nordøy I; Dörje C; Galteland E; Lind A; Hilli A; Aukrust P; Mjøen G
    BMC Infect Dis; 2021 Feb; 21(1):137. PubMed ID: 33526010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
    Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM
    Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.
    Wright RD; Bannerman F; Beresford MW; Oni L
    BMC Nephrol; 2020 Jun; 21(1):245. PubMed ID: 32605540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
    Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
    Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eculizumab deposits in vessel walls in thrombotic microangiopathy.
    Cassol CA; Brodsky SV; Satoskar AA; Blissett AR; Cataland S; Nadasdy T
    Kidney Int; 2019 Sep; 96(3):761-768. PubMed ID: 31345584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: Successful Treatment With Anti-C5 Monoclonal Antibody in a Japanese Adolescent Who Developed Thrombotic Microangiopathy After Autologous Bone Marrow Transplantation for Malignant Lymphoma.
    Shimizu S; Morohashi T; Kanezawa K; Yagasaki H; Takahashi S; Morioka I
    Front Pediatr; 2022; 10():908183. PubMed ID: 35859949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eculizumab treatment of thrombotic microangiopathy in a patient with ulcerative colitis.
    Øzbay LA
    Clin J Gastroenterol; 2020 Jun; 13(3):344-348. PubMed ID: 31612381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option.
    Román E; Mendizábal S; Jarque I; de la Rubia J; Sempere A; Morales E; Praga M; Ávila A; Górriz JL
    Nefrologia; 2017; 37(5):478-491. PubMed ID: 28946961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Eculizumab as rescue therapy for lupus nephritis-related thrombotic microangiopathy].
    Fani FM; Patera A; Delsante M; Rossi GM; Manenti L; Landini S; Regolisti G; Fiaccadori E
    G Ital Nefrol; 2020 Jun; 37(3):. PubMed ID: 32530153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.